HỘI CHỨNG TIM MẠCH - CHUYỂN HOÁ VÀ CHẤT LƯỢNG CUỘC SỐNG CỦA BỆNH NHÂN BỆNH PHỔI TẮC NGHẼN MẠN TÍNH ĐIỀU TRỊ NGOẠI TRÚ

Abstract

Backgrounds: Cardiometabolic syndrome (CMS) is one of the leading comorbidities of chronic obstructive pulmonary disease (COPD) with a prevalence of up to 50%. CMS may significantly affect the natural course of COPD and reduce the quality of life of patients with COPD. Objective: This study aimed to investigate the prevalence of CMS and its correlation with quality of life (QoL) in COPD patients. Methods: A cross-sectional study collected information from 128 outpatients with COPD at Nguyen Tri Phuong Hospital by using the Saint George respiratory symtom assessment questionnaire for patients with COPD (SGRQ-C). Results: The median age of the patients was 66 (61-71), with the majority being male (82%) and most having comorbidities (94,5%). Most patients had moderate to severe airflow obstruction (82,1%) and were in group E (53,1%). The mean SGRQ-C score was 39,41±20,62, in which the scores of three components of symptoms, activities, impacts were 47,75±18,72; 52,23±24,02 and 28,92±22,95, respectively. CMS occured in 62,5% of COPD patients, and 97,7% of patients had at least one diagnostic criterion for CMS with hypertension being the most common criterion. COPD patients with CMS had significantly lower QoL than those without CMS (42,35±20,29 vs. 34,5±20,44; p=0,029), particularly in the Activity component. Notably, the deterioration in QoL of COPD patients was associated with the number of CMS diagnotic criteria, and patients with CMS had a 3-fold higher risk of having poor QoL (SGRQ score ³25) compared to those without CMS (p=0,007). Conclusion: Both CMS and the increase of the number of metabolic abnormalities related to its diagnostic criteria impaired the QoL of COPD patients. The results of this study should be further eluciated in future studies.